;

This content has been developed by Galderma and is intended for Healthcare Professionals Only

Your expertise, meets ours.

The world’s most diverse range of individually designed dermal fillers and skinboosters.1-3 Matching your mastery, with their vision.

Restylane’s 26 years of experience is built on more than 55 million treatments worldwide,4 over two decades of safety data, and a robust clinical trial program, making it a well-established dermal filler range that you can trust for your patients. Restylane brings together two technologies, NASHA™ and OBT™, offering a truly personalised experience.

Adverse events include bleeding from the needle stick, bruising, redness/discoloration, itching,
swelling, pain, tenderness and tingling generally resolve spontaneously within 15 days after
injection. Please refer to the instructions for use within the product packaging prior to use for
full information on contraindications, adverse events and precautions.5,6,8-12

Restylane® SKINBOOSTERS™ helps boost hydration from within to improve elasticity13-15 and reduce skin roughness.16

Using the natural ability of Hyaluronic Acid (HA) to bind water molecules, locking moisture within the skin.13,14 The treatments infuse a thin layer of microdroplets of stabilised HA beneath the skin surface to provide long-term deep hydration. The treatments gradually build up the skin’s smoothness.17

With over 8 million treatments of Restylane® SKINBOOSTERS™ sold worldwide,22 it has a long-lasting effect for up to 12 months after 3 treatments,13 with top ups every 4-6 months for face, neck and décolletage.18-22

Injection-related reactions (including bruising, erythema, itching, swelling, pain or tenderness at the implant site) might occur after treatment. Typically resolution is spontaneous within a few days after treatment18,19

View All

References: 1. Data on file. (MA-43049). 2. Data on file. (MA-34483) 3. Nikolis A et al. Aesthet Surg J Open Forum. 2020; 2(1):1-12; 4. Data on file (MA-39680) 5. Restylane EU IFU 6. Restylane EYELIGHT EU IFU 7. Nikolis et al. Aesthet Surg J 2021; sjab284 8. Restylane LYFT EU IFU 9. Restylane REFYNE EU IFU 10. Restylane KYSSE EU IFU 11. Restylane DEFYNE EU IF 12. Restylane VOLYME EU IFU 13. Gubanova EI et al. Poster presented at IMCAS 2015 14. Distante F et al. Dermatol Surg 2009;35(S1):389–93 15. Gubanova EI et al. J Drugs Dermatol 2015;14(3):288–98 16. Kerscher M et al. Dermatol Surg 2008;34(5):720–6 17. Lee BM et al. Arch Plast Surg 2015;42(3):282–287 18. Restylane SKINBOOSTERS Vital EU IFU 19. Restylane SKINBOOSTERS Vital Light EU IFU 20. Nikolis A and Enright KM. Clin Cosmet Investig Dermatol 2018;11:467–475. 21. Streker M et al. J Drugs Dermatol 2013;12(9):990–4. 22. Galderma Data on File (MA-39929).

 

Adverse events should be reported. For the UK, Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website:
www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd,
Email: medinfo.uk@galderma.com Tel: +44 (0) 300 3035674


GB-ALZ-2300034 DOP August 2023